Literature DB >> 15595940

Health-related quality of life in blepharospasm or hemifacial spasm.

J Reimer1, K Gilg, A Karow, J Esser, G H Franke.   

Abstract

OBJECTIVES: Health-related quality of life (HRQL) has become an important outcome criterion of medical interventions, but was hardly studied in patients with facial spasms.
MATERIALS AND METHODS: Patients with blepharospasm or hemifacial spasm treated with botulinum toxin were included. A healthy control group sociodemografically matched to patients was established. Instruments applied included the SF-36 (global HRQL), the NEI-VFQ (disease-specific HRQL) and the Blepharospasm Rating/Disability Scale, the latter to patients only.
RESULTS: Thirty-one patients with blepharospasm and 21 patients with hemifacial spasm took part. The Blepharospasm Rating/Disability Scale revealed minor functional limitations, but identified some symptoms to be improved. In both patient groups global (both SF-36 Component Summaries) and disease-specific (eight of 12 subscales) HRQL were significantly impaired compared with controls.
CONCLUSION: HRQL should be integrated as core outcome criterion in treatment of patients with facial spasms. Assessment by a generic and a disease-specific instrument is recommended. Blackwell Munksgaard 2004

Entities:  

Mesh:

Year:  2005        PMID: 15595940     DOI: 10.1111/j.1600-0404.2004.00357.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  18 in total

Review 1.  The clinical importance of quality-of-life scores in patients with skull base tumors: a meta-analysis and review of the literature.

Authors:  Moran Amit; Avraham Abergel; Dan M Fliss; Ziv Gil
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

2.  Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy.

Authors:  Monika Rudzińska; Magdalena Wójcik; Andrzej Szczudlik
Journal:  J Neural Transm (Vienna)       Date:  2010-05-14       Impact factor: 3.575

Review 3.  Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  J Neural Transm (Vienna)       Date:  2012-01-10       Impact factor: 3.575

4.  Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin.

Authors:  Suwanna Setthawatcharawanich; Pornchai Sathirapanya; Kitti Limapichat; Kanitpong Phabphal
Journal:  Qual Life Res       Date:  2011-03-24       Impact factor: 4.147

5.  Videonystagmography as a tool to assess blepharospasm before and after botulinum toxin injection.

Authors:  Guillaume Casse; Jean-Paul Adenis; Jean-Pierre Sauvage; Pierre-Yves Robert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-26       Impact factor: 3.117

6.  [Quality of life - methodology and clinical practice aspects with a focus on ocular medicine].

Authors:  G H Franke; C Gall
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

Review 7.  Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.

Authors:  C Kenney; J Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2007-06-11       Impact factor: 3.575

8.  Medical Cannabis, a Beneficial High in Treatment of Blepharospasm? An Early Observation.

Authors:  Phillip M Radke; Ali Mokhtarzadeh; Michael S Lee; Andrew R Harrison
Journal:  Neuroophthalmology       Date:  2017-07-18

9.  FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm.

Authors:  Marcus K Blackburn; Randy D Lamb; Kathleen B Digre; A Gordon Smith; Judith E A Warner; Robert W McClane; Sanjeev D Nandedkar; Wendy J Langeberg; Richard Holubkov; Bradley J Katz
Journal:  Ophthalmology       Date:  2009-05       Impact factor: 12.079

10.  Validation of a Chinese version of disease specific quality of life scale (HFS-36) for hemifacial spasm in Taiwan.

Authors:  Yen-Chu Huang; Jun-Yu Fan; Long-Sun Ro; Rong-Kuo Lyu; Hong-Shiu Chang; Sien-Tsong Chen; Wen-Chuin Hsu; Chiung-Mei Chen; Yih-Ru Wu
Journal:  Health Qual Life Outcomes       Date:  2009-12-24       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.